MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
ordinary...
$330,912K
Proceeds from issuance of
ordinary shares pursuant...
$94,636K
Proceeds from issuance
pre-funded warrants, net of...
$46,938K
Proceeds from the
exercise of share options
$14,868K
Proceeds from the espp
$881K
Net cash provided by
financing activities
$488,235K
Effect of foreign
exchange rates on cash
$12K
Net increase in
cash, cash...
$300,036K
Canceled cashflow
$188,211K
Share-based compensation
expense
$24,973K
Accrued expenses and
other current...
$5,483K
Amortization of right-of-use
assets
$5,412K
Other assets
-$4,314K
Depreciation of property and
equipment
$3,440K
Prepaid expenses
-$1,149K
Accounts receivable
-$146K
Net cash used in
operating activities
-$187,493K
Net cash used in
investing activities
-$718K
Canceled cashflow
$44,917K
Net loss
-$204,378K
Purchases of property and
equipment
$718K
Deferred revenue
-$19,833K
Operating lease
liabilities
-$7,638K
Accounts payable
-$561K
Back
Back
Cash Flow
source: myfinsight.com
Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd. (WVE)